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ReviewFoxOs at the Crossroads of Cellular
Metabolism, Differentiation, and Transformation
al., 2001) and MyoD (Fulco et al., 2003), while cyto-
plasmic Sirtuins deacetylate enzymes (Starai et al., 2002)
and structural proteins like tubulin (North et al., 2003).
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tional effects, thus enabling cells to survive under condi-2 Ludwig Institute for Cancer Research
University of California, San Diego tions that would otherwise cause p53-dependent death.
Two studies now expand the repertoire of Sirt1 targetsSan Diego, California
by including FoxO. These papers show that FoxO is
acetylated in response to cellular stress by the acetyl-
transferase activity of the nuclear hormone receptor co-Forkhead transcription factors of the FoxO subfamily
are emerging as a shared component among path- activators Cbp and p300. Expression of Sirt1 causes
FoxO deacetylation. These data are consistent with theways regulating diverse cellular functions, such as dif-
ferentiation, metabolism, proliferation, and survival. genetic evidence in C. elegans, indicating that Daf16 is
downstream of Sir2.1. While these studies provide proofTheir transcriptional output is controlled via a two-
tiered mechanism of phosphorylation and acetylation. of principle that FoxO is modified through acetylation,
the functional consequences thereof are less clear.Modest alterations of this balance can result in pro-
found effects. The gamut of phenotypes runs from Motta et al. report that FoxO deacetylation decreases
expression of p27kip, a prominent FoxO target in theprotection against diabetes and predisposition to neo-
plasia, conferred by FoxO loss of function, to in- regulation of cell cycle progression (Motta et al., 2004).
Contrariwise, Brunet et al. propose that the effects ofcreased cellular survival and a marked catabolic re-
sponse associated with gain of function. deacetylation are target gene specific, such that expres-
sion of proapoptotic genes is inhibited, while expression
of genes that regulate cell cycle arrest (p27kip) and resis-In the roundworm C.elegans, insulin/insulin-like growth
tance to oxidative stress (MnSOD) is increased (Brunetfactor (IGF) signaling regulates metabolism, reproduc-
et al., 2004). Both papers propose that the net effect oftion, and life span. Mutations of the insulin/IGF receptor
deacetylation is to promote cellular survival under stressortholog Daf2 cause dauer, a characteristic arrest in
and protect against apoptosis by fine-tuning FoxO tran-diapause that results in increased life span. The effect
scription. As discussed below, the discrepancy betweenof Daf2 mutations can be rescued with complete pene-
the two reports underscores that more work will be re-trance by null alleles of Daf16, the ortholog of mamma-
quired to understand the impact of deacetylation onlian FoxO (Forkhead bOX-containing protein, O subfam-
FoxO function.ily) transcription factors. Moreover, gain-of-function
mutant alleles of the gene encoding the NAD-dependent
deacetylase Silent Information Regulator (Sir) 2.1 pro- Metabolic Functions of FoxO Proteins
long life span in a Daf16-dependent fashion (Finch and The physiologic functions of FoxO proteins, as deduced
Ruvkun, 2001). These twin observations provide the un- from loss- and gain-of-function experiments in trans-
derpinning for investigations of the role of FoxO proteins genic and knockout mice, are complex. Mice lacking the
in mammalian metabolism and life span. three main FoxO isoforms display remarkably different
Three of the four FoxOs (1, -3a, and –4) are substrates phenotypes (Hosaka et al., 2004): FoxO1 ablation is em-
of the serine/threonine kinase Akt, while FoxO6 lacks bryonic lethal due to defective angiogenesis. On the
some phosphorylation sites and exhibits a unique pat- other hand, haploinsufficiency of FoxO1 protects against
tern of subcellular localization. Genetic epistasis in C. insulin resistance caused by defective insulin signaling
elegans and biochemical evidence in mammalian cells (Nakae et al., 2002) and rescues diabetes due to pancre-
indicates that Akt regulates FoxO activity by inducing atic  cell failure caused by ablation of Insulin receptor
a prompt and sustained nuclear exclusion. This is an substrate 2 (Irs2) (Kitamura et al., 2002). Moreover, trans-
oversimplification, since inhibition of FoxO-dependent genic mice overexpressing a constitutively active FoxO1
transcription can be achieved with constitutively nuclear mutant in liver develop diabetes, presumably as a result
FoxO mutants, indicating that multiple mechanisms reg- of increased glucose production (Nakae et al., 2002).
ulate FoxO activity. FoxO3a has a selective effect on ovarian function. Abla-
There is broad consensus on the fact that Akt-depen- tion of FoxO3a causes premature ovarian failure as a
dent phosphorylation is crucial to the regulation of FoxO result of accelerated differentiation and consequent
function. However, the observation that worms with ex- depletion of primary ovarian follicles (Castrillon et al.,
tra copies of the Sir2.1 deacetylase have increased lon- 2003; Hosaka et al., 2004). The latter observation sug-
gevity and that Daf16 is epistatic to Sir2.1 gain-of-func- gests an additional mechanism to account for the well-
tion alleles raised the intriguing possibility that FoxO is known association among metabolism, life span, and re-
regulated by the seven mammalian Sir orthologs, or production.
Sirtuins (Sirt1–7). Nuclear Sirtuins can deacetylate tran- Metabolic studies point to FoxO1 as the long-sought
scription factors, such as p53 (Luo et al., 2001; Vaziri et insulin-regulated transcription factor responsible for in-
sulin action on gene expression (Figure 1). In liver, FoxO1
straddles two key pathways of insulin signaling, metabo-*Correspondence: da230@columbia.edu
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Figure 1. Synopsis of the Metabolic Actions
of FoxO1 in Different Target Tissues
lism and cellular proliferation. It promotes transcription of the terminal differentiation program. This requires
transient exclusion of FoxO from the nucleus. Accord-of genes that increase glucose production, acting in
concert with the Ppar coactivator Pgc1 (Puigserver ingly, a constitutively nuclear FoxO1 inhibits C2C12
myoblast differentiation, while a transcriptionally inac-et al., 2003). Since insulin control of hepatic glucose
production is key to the development and treatment of tive mutant is capable of partially rescuing the inhibition
of differentiation mediated by PI3K inhibition (Hribal etdiabetes, this makes FoxO1 a premier target for thera-
peutic intervention in this increasingly common disease. al., 2003). Interestingly, the same effect is seen in re-
sponse to activation of Sirt1 (Fulco et al., 2003), raisingMoreover, since diabetes increases oxidative stress
through the generation of reactive oxygen species, it is the possibility that the effects of FoxO and Sirt1 on
differentiation are epistatic. However, once the differen-possible that an increase in FoxO-dependent transcrip-
tion mediates the deleterious effects of hyperglycemia tiation process has commenced, a constitutively nuclear
FoxO mutant can increase myotube formation in primary(so-called “glucose toxicity”) as well. The potential im-
portance of FoxO1 in metabolic disease is underscored mouse myoblast cultures (Bois and Grosveld, 2003).
This study is seemingly in contrast with the findingsby the effect of FoxO1 haploinsufficiency to prevent
genetic (Kitamura et al., 2002; Nakae et al., 2002) as well in C2C12 cells, but in primary myoblasts, PI3K signaling
via Akt appears to have a paradoxical antidifferentiativeas environmental forms of diabetes (Nakae et al., 2003).
In addition, FoxO1 regulates organismal growth by con- effect, so the two systems are hardly comparable. None-
theless, these data emphasize that FoxO activity istrolling IGF binding protein-1 expression, which in turn
modulates IGFs bioavailability. FoxO can also affect tightly regulated during cellular differentiation. The im-
portance of this regulation is underscored by the factgrowth through its actions on the cell cycle, an effect
that is conserved from Drosophila to mammals (Junger that unchecked FoxO activity, as found in some chromo-
somal translocations, results in alveolar rhabdomyosar-et al., 2003; Puig et al., 2003).
comas (ARMS) (Xia et al., 2002), an aggressive pediatric
cancer thought to arise from the same progenitor cellsFoxOs and Cellular Differentiation
as striated muscle (see below).While the metabolic functions of FoxO proteins were to
The other end of the spectrum of FoxO functions issome extent predictable, based on work in C. elegans,
now explored in two papers addressing the relationshiptheir role in cellular differentiation was not. Evidence
between FoxO and muscular atrophy. Alterations offrom cultured cells and genetically modified mice indi-
muscle mass in wasting syndromes, including muscularcates that FoxOs integrate extracellular cues with the
atrophy, are invariably accompanied by the inductiontranscriptional cascade that controls differentiation of
of two ubiquin ligases, MAFbx (also known as Atrogin-1)pre-adipocytes (Nakae et al., 2003), myoblasts (Hribal
and MuRF1. Two studies now demonstrate that theseet al., 2003), pancreatic  cells (Kitamura et al., 2002),
ubiquitin ligases are FoxO targets, and that FoxO inhibi-and thymocytes (Leenders et al., 2000). These observa-
tion prevents their induction, opening a new front in thetions dovetail with the antidifferentiative effects FoxO3a
struggle to treat muscular atrophy (Sandri et al., 2004;in the female gonad, as described above (Castrillon et
Stitt et al., 2004). Thus, multiple pathways converge ontoal., 2003; Hosaka et al., 2004).
a single transcription factor to control different functionsNowhere has the gamut of FoxO functions been better
at different stages of differentiation. In differentiatingillustrated than in muscle development and function.
cells, a transient inhibition of FoxO activity appears toDuring myoblast differentiation, phosphoinositol 3-kinase
(PI3K) signaling leads to myoblast fusion and activation be a sine qua non to coordinate exit from the cell cycle
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Figure 2. Pathophysiologic Consequences of Altered FoxO Transcription
There is a consensus that phosphorylation inactivates FoxO, thus removing a constraint to cellular proliferation and potentially to tumorigenesis.
On the other hand, the functional consequences of acetylation are not clear, so this part of the diagram should be viewed as a working model,
and not as an established fact. Red circles represent phosphorylation sites, and yellow pentagons acetylation sites.
with activation of the terminal differentiation program. to increase the expression of Pax3 target genes (Xia et
al., 2002). However, mice bearing PAX3-FOXO1 trans-A sustained loss of FoxO function at this stage results
in unchecked proliferation and, potentially, in neoplastic genes or different versions of the Pax3-targeted PAX3-
FOXO1 mutant allele fail to develop tumors (Andersontransformation. On the other hand, unrestrained FoxO
activity in terminally differentiated cells appears to pro- et al., 2001; Lagutina et al., 2002; Relaix et al., 2003).
Thus, an alternative model has been proposed, sug-mote cellular senescence, but—when taken to ex-
tremes—can result in cellular atrophy and promote a gesting that FoxO loss of function is a pivotal event in
tumorigenesis. Since cancer can be thought of as acatabolic state (Figure 2).
perturbation of the critical balance between cell prolifer-
ation and cell death, disrupting a gene with roles inFoxO and Cancer
A role for FoxO family members in tumorigenesis was both cell cycle arrest and apoptosis could contribute to
cellular survival and confer an advantage to transformedfirst suggested by their involvement in two chromosomal
translocations associated with human cancer. In leuke- cells (Burgering and Kops, 2002). It is possible that the
disruption of one FOXO allele in ARMS results in a partialmia, FOXO2 (previously known as Af6q21) and FOXO4
(previously known as AFX) have both been shown to loss of FoxO protein and promotes cell survival and/or
transformation in cancer by altering its normal functionparticipate in chromosomal translocations with the Tri-
thorax-related transcription factor MLL (So and Cleary, to restrain cell cycle progression.
In addition to the chromosomal translocations de-2003). In solid tumors, the t(2;13) and t(1;13) transloca-
tions that uniquely associate with ARMS have been scribed above, there is growing evidence that FoxOs
play a role in other forms of cancer as well. The tumorshown to result in the fusion of the coding regions of
either PAX3 at 2q35 or PAX7 at 1q31 to FOXO1 at 13q14 suppressor gene PTEN has been shown to negatively
regulate FoxO through the PI3K/Akt pathway. In(Xia et al., 2002). Two models have been proposed to
explain the role of FOXO1 in tumorigenesis. One model PTEN-deficient cells, FoxO1 and FoxO3a are inactive,
and restoration of functional PTEN induces either apo-is predicated on the assumption that tumors arise from
a FoxO gain of function. The main evidence supporting ptosis or cell cycle arrest via upregulation of p27kip. This
effect can be mimicked by FoxOs, indicating that theythis view is that the FoxO1/Pax3 fusion protein is a
much more potent transcriptional activator than Pax3 act downstream of PTEN, potentially on cyclins D1 and
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D2 (Birkenkamp and Coffer, 2003). In prostate cancer, al., 2004). IB is important to regulate several cytokine-
where 60%–80% of tumors have mutations in PTEN, dependent pathways and is a prominent target of the
overexpression of FoxOs resulted in apoptosis through anti-inflammatory actions of salicylates (Yin et al., 1998).
direct induction of TRAIL, a proapoptotic member of FoxO phosphorylation by IB may thus provide a mech-
the tumor necrosis factor family (Modur et al., 2002). anistic link between cancer and inflammation.
Therefore, any decrease in PTEN decreases FoxO activ- In C.elegans, Daf16 straddles Daf2 (insulin/IGF recep-
ity and in this manner negatively affects direct targets tor) and Daf4/Daf7 (TGF) signaling pathways. A study
of FoxO, such as TRAIL and other indirect targets, ulti- by Seoane and colleagues now demonstrates that a
mately promoting tumor cell survival. It has also been similar interaction occurs in mammalian cells, where
shown in prostate cancer that androgen receptor and FoxO acts at the intersection of three critical pathways—
FoxO1 are capable of forming a complex, which impairs the Smad, PI3K, and FoxG1 pathways (Seoane et al.,
the DNA binding activity of FoxO1, thereby reducing its 2004). The growth inhibitory gene p21Cip1 is activated
ability to induce cell cycle arrest and apoptosis. The when Smad proteins, mediators of TGF signaling, form
same pattern of response to FoxO proteins can be dem- a complex with FoxO proteins. This process is negatively
onstrated in a variety of cell types that are not necessar- regulated by PI3K and positively regulated by FoxG1, a
ily PTEN deficient. Whether cells demonstrate cell cycle member of a different subfamily of Fox genes. FoxG1
arrest or the apoptotic phenotype is likely to reflect dif- binds to the FoxO-Smad complexes to block p21Cip1
ferences in cell types and/or physiological conditions. expression. The implication for cancer is clear. While
In this respect, it should be noted that FoxOs are able mutations of TGF have been described in some can-
to induce apoptosis via FasL and BIM. cers, more often tumor cells cease to maintain the cyto-
In chronic myeloid leukemia, cytokine- and BCR/ABL- static response to TGF. In the absence of the cytostatic
mediated inhibition of TRAIL occurs through FoxO3a response, TGF becomes a potent inducer of cell prolif-
phosphorylation. Moreover, FoxO3a has been impli- eration, invasion, and metastasis. Seoane et al. show
cated as a downstream effector of STI571-induced cell that glioblastoma cells have increased levels of FoxG1
cycle arrest in BCR/ABL-expressing cells. Finally, and PI3K/Akt activity, resulting in the suppression of
FoxO1 phosphorylation is associated with significantly p21Cip1 and cytostasis and promoting cell survival and
shorter survival of patients with AML, leading to the proliferation, precisely the desired strategy for success-
suggestion that phospho-FoxO1 may be a useful marker ful tumor growth and spread (Seoane et al., 2004). Inter-
for identifying AML patients likely to have unfavorable estingly, p21Cip1 is also a prominent FoxO target during
clinical outcomes. pre-adipocyte differentiation (Nakae et al., 2003).
FoxO3a activity has been shown to elevate p27kip ex- In the studies described above, inactivation of FoxO
pression and induce cell cycle arrest. FoxO3a and appears to be an important step in carcinogenic trans-
FoxO4 have also been shown to inhibit the cell cycle formation and would argue that FoxO genes be classi-
through downregulation of cyclin D by a p27kip-indepen- fied as tumor suppressors. Cancer-related drug discov-
dent mechanism. Thus, p27kip is not required for FoxO- ery has been focused on inhibitors of oncoproteins that
induced cell cycle arrest, but appears to buttress the are activated in tumor cells. One of the best-known
antiproliferative effect of FoxO. examples is Gleevac, the inhibitor of the leukemia-asso-
In breast cancer, FoxO3a has been shown to upregu- ciated BRC/ABL fusion gene product. Developing chem-
late BIM, a BH3 domain protein very effective at inducing ical molecules that act to restore the function of a defec-
apoptosis. In paclitaxel-sensitive breast cancer, pacli- tive tumor suppressor gene would seem to pose a more
taxel appears to upregulate FoxO3a, which subse- difficult problem. However, recently Kau et al. identified
quently increases BIM expression, ultimately decreas- several small molecules that act as inhibitors of FoxO1
ing cell survival and contributing to the tumor response nuclear export in PTEN-deficient cells (Kau et al., 2003).
to paclitaxel. On the other hand, stimulation of p21-
These molecules fall into two classes: general inhibitors
activated kinase-1 (Pak-1) and estrogen receptor- by
of the nuclear export receptor CRM1 and specific inhibi-
estrogen treatment in mammary cancer cells promotes
tors of the PI3K/Akt-dependent export pathway (Figurecell survival by inducing phosphorylation and nuclear
2). Whether any of these compounds will make their wayexclusion of FoxO1 in a Pak1-dependent manner (Birk-
to the clinic remains to be seen. However, given theenkamp and Coffer, 2003).
variety of cancers in which FoxO proteins are likely toIn their investigation of the relationship between Akt
play a role, the prospect of potential treatment modal-phosphorylation (pAkt) and FoxO3a expression in pri-
ities aimed at restoring FoxO activity is an exciting one.mary breast tumors, Hu et al. found that in some pAkt-
negative tumors, FoxO3a was excluded from the nu-
At the Crossroads of Metabolism and Neoplasiacleus. These same tumors exhibited high expression of
The biology of FoxO transcription factors provides aIB kinase , a key modulator of the NF-B proinflamma-
glimpse into the complex relationship among cellulartory pathway, and had a poor survival rate. The study
proliferation, transformation, and metabolism. In hu-goes on to show that FoxO3a is a direct target of the
mans, epidemiological studies indicate that rates of can-IB kinase. Phosphorylation by IB causes cellular relo-
cer prevalence increase with increasing body masscalization of FoxO3a to the cytoplasm, accompanied
(Calle et al., 2003). Does this association reflect a com-by ubiquitination and degradation by the proteasome
mon etiology? The transcriptional thread activated bypathway. Furthermore, overexpression of FoxO3a can
FoxO represents a potential unifying mechanism to reg-override IB stimulation of cell cycle progression, prolif-
ulate both cellular differentiation and metabolism. Thus,eration, and tumorigenesis in mice, indicating that—in
this setting—FoxO3a acts as a tumor suppressor (Hu et the FoxO target p21cip is critical for both TGF-depen-
Review
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dent transformation and insulin-dependent adipogen- FoxO acetylation, the report by Brunet and colleagues
indicates that only a fraction of endogenous FoxO isesis, providing a mechanism by which alterations of
FoxO function could tip the balance between cellular bound to Sirt1 at any given time. If so, this would suggest
that small changes in the amount of deacetylated FoxOdifferentiation and neoplastic transformation. Another
mechanism could be envisioned to involve FoxO inacti- have major consequences on cellular functions and indi-
cate that deacetylation is paramount in regulating FoxOvation by I, as the latter also mediates insulin resis-
tance (Yuan et al., 2001). activity. The studies on the FoxO/Sirt1 interaction repre-
sent an important stepping stone toward the demonstra-From a therapeutic standpoint, the identification of
acetylation-dependent mechanisms of FoxO regulation tion that control of vertebrate life span, cell differentia-
tion, metabolism, and reproduction can be ascribed toexpands the potential repertoire of drugs by which FoxO
activity could be modulated to include HDAC inhibitors. FoxO target genes. The challenge is now to address
how seemingly contrasting in vivo functions of FoxOSince these compounds are coming to the fore as anti-
neoplastic agents, the present findings raise the ques- can yield a coordinated organismal response when
modulated through acetylation.tion of whether they could be pressed into service
against the raising tide of metabolic diseases. In addi-
Referencestion, as Sirtuin agonists have been shown to control
metabolism in yeast, it is worth exploring the idea that
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